Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a clinical-stage biopharmaceutical company focused on discovering and developing novel live biotherapeutic products to improve patient outcomes in medically vulnerable populations. The company's website is www.seresrx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Seres Therapeutics, Inc. does
In the company’s own words
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a clinical-stage biopharmaceutical company focused on discovering and developing novel live biotherapeutic products to improve patient outcomes in medically vulnerable populations. The company's website is www.seresrx.com.
Seres pioneered the development of VOWST, the first FDA-approved orally administered microbiome biotherapeutic, which was sold to Nestlé Health Science in September 2024. The company has established field-leading capabilities and platforms powered by proprietary human datasets to advance a portfolio of live biotherapeutic candidates targeting diseases associated with the mucosal barrier-immune interface.
The company's pipeline consists of three primary programs. SER-155, the most advanced candidate, is designed to decolonize gastrointestinal pathogens, improve epithelial barrier integrity, and prevent bacterial bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplantation. In December 2024, the FDA granted Breakthrough Therapy designation to SER-155 for reducing bloodstream infections in allo-HSCT patients. SER-603 targets inflammatory bowel disease, including ulcerative colitis and Crohn's disease, through non-immunosuppressive mechanisms. SER-147 is designed to prevent bacterial infections in patients with chronic liver disease.
Seres has developed the MbTx Platform, a proprietary reverse translational discovery and development system that integrates high-resolution human clinical data analysis, preclinical screening using human cell-based assays, and a functionally characterized strain library of bacterial isolates. The company maintains manufacturing capabilities specifically designed for live biotherapeutics production under current Good Manufacturing Practices standards at its Cambridge, Massachusetts facility.
The company was founded by Flagship Pioneering and has assembled experienced management with core capabilities in live biotherapeutics, drug development, regulatory approval, manufacturing, and commercialization. Seres has established long-standing collaborations with leading academic medical centers, including Memorial Sloan Kettering Cancer Center, to advance clinical development and generate translational data supporting its therapeutic approach across infectious disease and inflammatory and immune disease indications.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1609809
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Seres Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Seres Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Seres Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Seres Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Seres Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”